Abstract:Epilepsy Currents, Ahead of Print. Association of Plasma Aβ42/Aβ40 Ratio and Late-Onset Epilepsy: Results From the Atherosclerosis Risk in Communities StudyJohnson EL, Sullivan KJ, Schneider ALC, Simino J, Mosley TH, Kucharska-Newton A, Knopman DS, Gottesman RF. Neurology. 2023 Sep 26;101(13):e1319-e1327. doi:10.1212/WNL.0000000000207635. Epub 2023 Aug 4. PMID: 37541842Background and Objectives: The objective of this study was to determine the relationship between plasma β-amyloid (Aβ), specifically the ratio of 2 Aβ peptides (the Aβ42/Aβ40 ratio, which correlates with increased accumulation of Aβ in the central nervous system [CNS]), and late-onset epilepsy (LOE). Methods: We used Medicare fee-for-service claims codes from 1991 to 2018 to identify cases of LOE among 1424 Black and White men and women enrolled in the Atherosclerosis Risk in Communities (ARIC) study cohort. The Aβ42/Aβ40 ratio was calculated from plasma samples collected from ARIC participants from 1993 to 1995 (age 50-71 years) and 2011 to 2013 (age 67-90 years). We used survival analysis accounting for the competing risk of death to determine the relationship between late-life plasma Aβ42/Aβ40, and its change from midlife to late life, and the subsequent development of epilepsy. We adjusted for demographics, the apolipoprotein e4 genotype, and comorbidities, including stroke, dementia, and head injury. A low plasma ratio of 2 Aβ peptides, the Aβ42/Aβ40 ratio, correlates with low CSF Aβ42/Aβ40 and with increased accumulation of Aβ in the CNS. Results: A decrease in plasma Aβ42/Aβ40 ratio from midlife to late life, but not an isolated measurement of Aβ42/Aβ40, was associated with the development of epilepsy in later life. For every 50% reduction in Aβ42/Aβ40, there was a 2-fold increase in the risk of epilepsy (adjusted subhazard ratio 2.30, 95% CI: 1.27-4.17). Discussion: A reduction in plasma Aβ42/Aβ40 is associated with an increased risk of subsequent epilepsy. Our observations provide a further validation of the link between Aβ, hyperexcitable states, and LOE.Similar Brain Proteomic Signatures in Alzheimer's Disease and EpilepsyLeitner D, Pires G, Kavanagh T, Kanshin E, Askenazi M, Ueberheide B, Devinsky O, Wisniewski T, Drummond E. Acta Neuropathol. 2024 Jan 30;147(1):27. doi:10.1007/s00401-024-02683-4. PMID: 38289539The prevalence of epilepsy is increased among Alzheimer's disease (AD) patients and cognitive impairment is common among people with epilepsy. Epilepsy and AD are linked but the shared pathophysiological changes remain poorly defined. We aim to identify protein differences associated with epilepsy and AD using published proteomics datasets. We observed a highly significant overlap in protein differences in epilepsy and AD: 89% (689/777) of proteins altered in the hippocampus of epilepsy patients were significantly altered in advanced AD. Of the proteins altered in both epilepsy and AD, 340 were altered in the same direction, while 216 proteins were altered in the opposite direction. Synapse and mitochondrial proteins were markedly decreased in epilepsy and AD, suggesting common disease mechanisms. In contrast, ribosome proteins were increased in epilepsy but decreased in AD. Notably, many of the proteins altered in epilepsy interact with tau or are regulated by tau expression. This suggests that tau likely mediates common protein changes in epilepsy and AD. Immunohistochemistry for Aβ and multiple phosphorylated tau species (pTau396/404, pTau217, and pTau231) showed a trend for increased intraneuronal pTau217 and pTau231 but no phosphorylated tau aggregates or amyloid plaques in epilepsy hippocampal sections. Our results provide insights into common mechanisms in epilepsy and AD and highlight the potential role of tau in mediating common pathological protein changes in epilepsy and AD.

Subclinical epileptiform discharges in Alzheimer's disease are associated with increased hippocampal blood flow

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Increased Apparent Blood Flow and Volume of the Choroid Plexus in the Alzheimer’s Disease Patients

Detection of subclinical epileptiform discharges in Alzheimer's disease using long-term outpatient EEG monitoring

Incidence and impact of subclinical epileptiform activity in Alzheimer's disease

Subclinical epileptiform activity in the Alzheimer continuum: association with disease, cognition and detection method

Alzheimer Disease and Epilepsy

Association of Seizure Foci and Location of Tau and Amyloid Deposition and Brain Atrophy in Patients With Alzheimer Disease and Seizures

Subclinical epileptiform activity and sleep disturbances in Alzheimer's disease

Levetiracetam Increases Hippocampal Blood Flow in Alzheimer’s Disease As Measured by Arterial Spin Labelling MRI

Paroxysmal slow cortical activity in Alzheimer’s disease and epilepsy is associated with blood-brain barrier dysfunction

Alzheimer Disease and Epilepsy A Mendelian Randomization Study

Abnormal gamma phase-amplitude coupling in the parahippocampal cortex is associated with network hyperexcitability in Alzheimer's disease

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism

Epilepsy and epileptiform activity in late-onset Alzheimer disease: clinical and pathophysiological advances, gaps and conundrums

The Role of Epileptic Activity in Alzheimer's Disease

Regional cerebral blood flow in focal cortical epilepsy

Reduced Resting-State Cortical Alpha Connectivity Reflects Distinct Functional Brain Dysconnectivity in Alzheimer's Disease and Mild Cognitive Impairment

The Crossroads Between Alzheimer's Disease Pathophysiology and Epilepsy

Aberrant vascular architecture in the hippocampus correlates with tau burden in mild cognitive impairment and Alzheimer’s disease

Alterations in theta-gamma coupling and sharp wave-ripple, signs of prodromal hippocampal network impairment in the TgF344-AD rat model